NCT03785522 - A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia | Biotech Hunter

Enrollment

597

Participants

Timeline

Start Date

December 23, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin degludec

Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.

Trial Locations (21)

11525

Novo Nordisk Investigational Site, Riyadh

12311

Novo Nordisk Investigational Site, Riyadh

12381

Novo Nordisk Investigational Site, Riyadh

12625

Novo Nordisk Investigational Site, Riyadh

14212

Novo Nordisk Investigational Site, Riyadh

14611

Novo Nordisk Investigational Site, Riyadh

22231

Novo Nordisk Investigational Site, Jeddah

22252

Novo Nordisk Investigational Site, Jeddah

23216

Novo Nordisk Investigational Site, Jeddah

23521

Novo Nordisk Investigational Site, Jeddah

24243

Novo Nordisk Investigational Site, Mecca

31911

Novo Nordisk Investigational Site, AL Qateef

32236

Novo Nordisk Investigational Site, Dammam

32253

Novo Nordisk Investigational Site, Dammam

32263

Novo Nordisk Investigational Site, Dammam

34234

Novo Nordisk Investigational Site, Khobar

34425

Novo Nordisk Investigational Site, Khobar

35718

Novo Nordisk Investigational Site, Jubail

36364

Novo Nordisk Investigational Site, Ihsa

22324,

Novo Nordisk Investigational Site, Jeddah

Unknown

Novo Nordisk Investigational Site, Jeddah